Johannes Jacob Piete  Kastelein net worth and biography

Johannes Kastelein Biography and Net Worth

Professor Dr. John Kastelein is founder and Chief Scientific Officer of NewAmsterdam Pharma and a member of the Executive Board. Prof. Dr. Kastelein is Emeritus Professor of Medicine at the Department of Vascular Medicine at the Academic Medical Center of the University of Amsterdam, where he held the office of Strategic Chair of Genetics of Cardiovascular Disease. Prof. Dr. Kastelein has published more than 1,320 research papers in peer-reviewed journals, including Nature Genetics, The Lancet, New England Journal of Medicine, JAMA, and Circulation, with a Hirsch index of 122 in January 2020. His research has been cited more than 74,800 times. Prof. Dr. Kastelein is a member of the steering committees of numerous lipid-lowering and cardiovascular intervention trials. His main interest is in the development of novel therapies for cardiovascular diseases and the genetic basis of dyslipidemia. Prof. Dr. Kastelein is CEO of the Vascular Research Network, a site maintenance organization comprised of 50 hospitals in the Netherlands, involved in clinical trials for cardiometabolic disease. He is president of the Dutch Atherosclerosis Society and the National Scientific Committee on Familial Hypercholesterolemia and a Fellow of the European Society of Cardiology. In 2010, he was awarded the prestigious Dutch Heart Association award of €1 million, and, in 2011, he was awarded the ZonMw Parel for his research in the field of gene therapy. Additionally, Prof. Dr. Kastelein is key advisor to a number of biotech and pharmaceutical companies. Prof. Dr. Kastelein earned his doctorate in medicine with honors from the University of Amsterdam, trained in internal medicine at the Academic Medical Center of the University of Amsterdam, and trained in lipidology and molecular biology at the University of British Columbia in Vancouver.

How old is Johannes Jacob Piete Kastelein?

Dr. Kastelein is currently 70 years old. There are 6 older executives and no younger executives at NewAmsterdam Pharma. Learn More on Johannes Jacob Piete Kastelein's age.

How do I contact Johannes Jacob Piete Kastelein?

The corporate mailing address for Dr. Kastelein and other NewAmsterdam Pharma executives is TWO UNION SQUARE 601 UNION STREET SUITE 3200, SEATTLE WA, 98101. NewAmsterdam Pharma can also be reached via phone at 352062971 and via email at max.nowicki@frazierhealthcare.com. Learn More on Johannes Jacob Piete Kastelein's contact information.

Has Johannes Jacob Piete Kastelein been buying or selling shares of NewAmsterdam Pharma?

Johannes Jacob Piete Kastelein has not been actively trading shares of NewAmsterdam Pharma during the last quarter. Most recently, Johannes Jacob Piete Kastelein sold 190,476 shares of the business's stock in a transaction on Tuesday, March 26th. The shares were sold at an average price of $21.50, for a transaction totalling $4,095,234.00. Learn More on Johannes Jacob Piete Kastelein's trading history.

Who are NewAmsterdam Pharma's active insiders?

NewAmsterdam Pharma's insider roster includes Juliette Audet (Insider), Michael Davidson (CEO), Johannes Kastelein (Insider), Louise Kooij (CAO), and James Topper (Director). Learn More on NewAmsterdam Pharma's active insiders.

Are insiders buying or selling shares of NewAmsterdam Pharma?

During the last twelve months, NewAmsterdam Pharma insiders bought shares 4 times. They purchased a total of 18,538 shares worth more than $369,041.40. During the last twelve months, insiders at the sold shares 11 times. They sold a total of 832,206 shares worth more than $19,296,828.63. The most recent insider tranaction occured on March, 4th when CAO Louise Frederika Kooij sold 150,000 shares worth more than $3,055,500.00. Insiders at NewAmsterdam Pharma own 19.5% of the company. Learn More about insider trades at NewAmsterdam Pharma.

Information on this page was last updated on 3/4/2025.

Johannes Jacob Piete Kastelein Insider Trading History at NewAmsterdam Pharma

See Full Table

Johannes Jacob Piete Kastelein Buying and Selling Activity at NewAmsterdam Pharma

This chart shows Johannes Jacob Piete Kastelein's buying and selling at NewAmsterdam Pharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$4M-$2M$0$2M$4MTotal Insider BuyingTotal Insider Selling

NewAmsterdam Pharma Company Overview

NewAmsterdam Pharma logo
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Read More

Today's Range

Now: $23.37
Low: $22.76
High: $24.00

50 Day Range

MA: $21.95
Low: $17.53
High: $26.04

2 Week Range

Now: $23.37
Low: $15.19
High: $27.29

Volume

1,382,997 shs

Average Volume

489,761 shs

Market Capitalization

$2.57 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A